Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT04304261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Registry
-
NCT04304261
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04304261. Randomized; no masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2023-12-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
- Acronym
- ESCDP
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Cognitive Functions Confusion
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Third Military Medical University
Record details
- Record id
cardio:ct-nct04304261- Content hash
acd4fd820121b95d3af93bbcd0173673b04ff17680ad5adc2b4be0d421e5ddbe